A p38 MAP kinase inhibitor. VX-702 dose-dependently inhibited the production of IL-6, IL-1β and TNFα (IC₅₀ = 59, 122 and 99 ng/ml, respectively). Pre-incubation of platelets with VX-702 (1 µM) completely or partially inhibited platelet agonist induced p38 activation (IC₅₀= 4 to 20 nM).

1. Goldstein DM  et al. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 53:2345-53 (2010).

2. Kuliopulos A  et al. Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thromb Haemost 92:1387-93 (2004).